As of June 13, 2025, Endo International PLC (ENDP) reports a Gross Margin of 71.87%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Endo International PLC's Gross Margin
Over recent years, Endo International PLC's Gross Margin has shown a moderate pattern. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2021-12-31 | 71.87% |
| 2020-12-31 | 50.31% |
| 2019-12-31 | 46.15% |
| 2018-12-31 | 44.63% |
| 2017-12-31 | 35.76% |
This slight upward trend highlights how Endo International PLC manages its operational efficiency and pricing power over time.
Comparing Endo International PLC's Gross Margin to Peers
To better understand Endo International PLC's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Endo International PLC (ENDP) | 71.87% |
| NGM Biopharmaceuticals Inc (NGM) | 7775.20% |
| Theravance Biopharma Inc (TBPH) | 100.00% |
| Corcept Therapeutics Inc (CORT) | 98.39% |
| Innoviva Inc (INVA) | 89.80% |
| Supernus Pharmaceuticals Inc (SUPN) | 89.57% |
Compared to its competitors, Endo International PLC's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.